Abstract
Pharmacists are using a variety of techniques to ensure that pharmaceuticals produced by recombinant technology improve patient outcomes without blowing pharmacy budgets. Recombinant granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were the focus of several presentations at the 28th Midyear Clinical Meeting of the American Society of Hospital Pharmacists, held in Atlanta, Georgia last December. Key areas in which pharmacists participate in optimising the use of these drugs include exploiting synergistic effects of treatment, determining treatment guidelines and minimising inappropriate use of these high-price agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
